Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Acute myeloid leukemia
Consolidation therapy
Cytarabine dosage
Real-world data
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
14
08
2022
accepted:
09
09
2022
medline:
19
7
2023
pubmed:
29
9
2022
entrez:
28
9
2022
Statut:
ppublish
Résumé
Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single-agent cytarabine in consolidation therapy remains elusive. Here, we assessed the impact of different dosages of cytarabine consolidation after 7 + 3 induction on outcome in a large real-world data set from the German Study Alliance Leukemia-Acute Myeloid Leukemia (SAL-AML) registry. Patients between 18 and 64 years of age, registered between April 2005 and September 2020, who attained complete remission after intensive induction and received at least one consolidation cycle with intermediate (IDAC) or high-dose cytarabine (HiDAC) were selected. To account for differences in patient and disease characteristics between both groups, the average treatment effect was estimated by propensity score weighting. Six-hundred-forty-two patients received HiDAC consolidation with median dosage of 17.6 (IQR (interquartile range), 16.5-18.0) g/m This retrospective analysis suggests no significant benefit of high-dose cytarabine compared to intermediate dosages in consolidation for AML patients under 65 years of age, independent of ELN risk group. NCT03188874.
Identifiants
pubmed: 36167894
doi: 10.1007/s00432-022-04356-9
pii: 10.1007/s00432-022-04356-9
pmc: PMC10349710
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Banques de données
ClinicalTrials.gov
['NCT03188874']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4611-4621Informations de copyright
© 2022. The Author(s).
Références
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179
pubmed: 9751631
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terre C, Fenaux P, Castaigne S, Dombret H et al (2011) Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 96:837–844
doi: 10.3324/haematol.2010.036921
pubmed: 21459791
pmcid: 3105645
Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, Ho AYL, Chuan WG, Lao Z, He F (2021) High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol 194:140–144
doi: 10.1111/bjh.17462
pubmed: 33843048
Lowenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26–28
doi: 10.1182/blood-2012-07-444851
pubmed: 23287624
Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027–1036
doi: 10.1056/NEJMoa1010222
pubmed: 21410371
Magina KN, Pregartner G, Zebisch A, Wolfler A, Neumeister P, Greinix HT, Berghold A, Sill H (2017) Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood 130:946–948
doi: 10.1182/blood-2017-04-777722
pubmed: 28679736
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896–903
doi: 10.1056/NEJM199410063311402
pubmed: 8078551
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117:2366–2372
doi: 10.1182/blood-2010-07-295279
pubmed: 21190996
Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26:4603–4609
doi: 10.1200/JCO.2007.14.0418
pubmed: 18559876
pmcid: 2653132
Schaich M, Rollig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H et al (2011) Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29:2696–2702
doi: 10.1200/JCO.2010.33.7303
pubmed: 21606413
Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C, Thiede C, Hanel M, Schafer-Eckart K, Aulitzky W et al (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 31:2094–2102
doi: 10.1200/JCO.2012.46.4743
pubmed: 23630210
Tangchitpianvit K, Rattarittamrong E, Chai-Adisaksopha C, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Tantiworawit A, Norasetthada L (2021) Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients. Hematology 26:355–364
doi: 10.1080/16078454.2021.1912949
pubmed: 33853503
Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C et al (2011) Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118:1754–1762
doi: 10.1182/blood-2011-04-349258
pubmed: 21690555